Pharmaceutical compositions for treating painful neuropathy and methods of treating same

A neuropathy, nerve tissue technology, used in drug combinations, nervous system diseases, pharmaceutical formulations, etc.

Inactive Publication Date: 2006-05-31
NEUROMOLECULAR INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite advances in control of peripheral viral replication and treatment of opportunistic infections, HAART does not provide complete protection against HAD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] Design / Methods: Mixed neuron / glia cortical cultures were mixed to contain 30-40% neurons. The cultures were prepared from embryonic day 16-17 mice and used 17 days after inoculation. Cultures were exposed to 200 pM gp120 in the presence or absence of EPO (10 U / ml) for 24 hours. Apoptotic neurons were identified by labeling with MAP-2, a neuron-specific marker, and TUNEL staining plus morphology. Intracellular signaling pathways were identified by immunoblotting and immunocytochemistry for Akt and GSK3. Transduction of a dominant repressive form of Akt was achieved with an adenoviral vector.

[0093] Results: HIV / gp120 increased neuronal apoptosis compared to controls (506% vs. 114%). Pre-incubation with EPO for 3 hours reduced apoptosis to 387%. Cell signaling in the neuroprotection of EPO against gp120 was next investigated. Exposure to gp120 leads to dephosphorylation of GSK3. The neuroprotective effects of EPO were largely blocked by inhibition of Akt achieved ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides novel methods and compositions for the treatment and prevention of HIV-associated dementia (HAD), mild cognitive / motor disturbance (MCMD), neuropathic pain associated with HAD, or neuropathic pain from other causes.

Description

field of invention [0001] The present invention relates to compositions and methods for treating painful neuropathies comprising erythropoietin (EPO). Background of the invention [0002] One symptom of human immunodeficiency virus (HIV) is a syndrome of cognitive and motor dysfunction known as HIV-associated dementia (HAD). While on highly active antiretroviral therapy (HAART), a milder form of neurological dysfunction called mild cognitive / motor disturbance (MCMD) is more common than overt dementia. HAD and MCMD are important independent risk factors for death in acquired immunodeficiency syndrome (AIDS) (Kaul, M., et al., Nature 410:988-994 (2001), and Power, C., et al. Can . J. Neurol. Sci. 29.19-32, (2002)). Despite advances in the control of peripheral viral replication and the treatment of opportunistic infections, HAART does not provide complete protection against the development of HAD. Summary of the invention [0003] The present invention relates to composit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61KA61K38/17A61K38/18C07K14/505
CPCA61K38/1816A61P25/00A61P25/04A61P25/14A61P25/28A61P31/18A61P43/00A61K31/7048A61K38/18C07K14/435
Inventor 斯图尔特·利普顿莫瑞特·迪吉卡利奥格卢
Owner NEUROMOLECULAR INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap